Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Verekitug, UPB-101, Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis, Thymic Stromal Lymphopoetin Receptor, Lung Inflammation, Biologic, Monoclonal Antibody, VENTURE
Brief summary
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Detailed description
This is a global, multicenter study to assess the efficacy, safety, and tolerability of verekitug in participants with moderate-to-severe COPD. Adult participants are planned to be enrolled and will be allocated randomly in a 1:1:1 ratio to one of two dose levels of verekitug or placebo, in addition to their COPD background medications. The study consists of a screening period of approximately 4 weeks; treatment periods of between 60 weeks and up to 108 weeks; and a follow-up period, with the end-of-study visit 16 weeks after last dose.
Interventions
DRUGVerekitug
Verekitug (UPB-101) formulated solution
OTHERPlacebo
Matching Placebo to Verekitug (UPB-101)
Sponsors
Upstream Bio Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Physician diagnosis of COPD for \>12 months. * Current or former smokers with a smoking history of 10 pack-years or more. * Post-bronchodilator FEV1/ Forced Vital Capacity (FVC) ratio \<0.70 and predicted post-bronchodilator FEV1 \>30% and ≤80%. * Modified Medical Research Council dyspnea scale Grade ≥2. * Background triple therapy (Inhaled Corticosteroid \[ICS\], Long-Acting Beta Agonist \[LABA\], Long-Acting Muscarinic Antagonist \[LAMA\]) for 3 months before randomization with a stable dose of medications for 1 or more months prior to Visit 1. * Are ≥80% compliant with background therapy during the screening period.
Exclusion criteria
* Moderate or severe exacerbation of COPD within 4 weeks prior to or during the screening period. * Respiratory tract infection within 4 weeks prior to or during the screening period. * Treatment with oxygen of \>4 liters/minute. Nocturnal oxygen use for sleep apnea is allowed. * Systemic or biologic immunosuppressant therapy to treat inflammatory disease or autoimmune disease within 24 weeks or 5 half-lives prior to Visit 1, whichever is longer, with the exception of oral corticosteroids. Treatment with cyclophosphamide and rituximab within 12 months of Visit 1. * Current diagnosis of asthma according to the 2023 Global Initiative for Asthma guidelines or other accepted guidelines * History or evidence of a clinically meaningful pulmonary condition other than COPD (e.g., pulmonary fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts. * Chronic hypercapnia requiring Bilevel Positive Airway Pressure (BiPAP). Participants requiring BiPAP periodically for an acute COPD exacerbation are not excluded. * Any of the following in the previous 6 months prior to Visit 1: acute myocardial infarction, transient ischemic attack or stroke, hospitalization for any cardiovascular or cerebrovascular event, pulmonary embolism, deep vein thrombosis and cardiac arrhythmias including paroxysmal (e.g., intermittent). Participants with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blocker, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) and stable appropriate level of anticoagulation for at least 6 months may be considered for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annualized rate of moderate or severe COPD exacerbation events | From Day 1 (Baseline) up to Week 108 |
Secondary
| Measure | Time frame |
|---|---|
| Change in pre-bronchodilator forced expiratory capacity in 1 second (FEV1) | From Day 1 (Baseline) to Week 60 |
| Annualized rate of severe COPD exacerbation events | From Day 1 (Baseline) up to Week 108 |
| Change in St. George's Respiratory Questionnaire (SGRQ) total score | From Day 1 (Baseline) to Week 60 |
| Proportion of participants with SGRQ improvement of >4 points | At Week 60 |
| Incidence of treatment-emergent adverse events and serious adverse events | From Day 1 (Baseline) up to Week 112 |
Countries
Argentina, Bulgaria, Chile, Czechia, Georgia, Germany, Hungary, India, Ireland, Latvia, Lithuania, Malaysia, Philippines, Poland, Romania, Serbia, Slovakia, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States
Contacts
STUDY_DIRECTORJustin Salciccioli, MD
Upstream Bio
Outcome results
None listed